Overview A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Status: Recruiting Trial end date: 2025-09-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy. Phase: Phase 2/Phase 3 Details Lead Sponsor: Biohaven Therapeutics Ltd.